Simple Summary Papillary thyroid carcinoma (PTC) represents 80–90% of all differentiated
thyroid carcinomas. PTC has a high rate of gene fusions and mutations, which can influence …

Targeted inhibitors of neurotropic tyrosine kinases are highly effective in selected patients
with gene fusions involving NTRK1, NTRK2, or NTRK3. These fusions are consistently …

Simple Summary Thyroid tumors that derive from follicular cells are not a homogeneous
entity, showing variable morphological appearance and different degrees of differentiation …

Background: Pediatric papillary thyroid carcinoma (PTC) is a rare malignancy, but with
increasing incidence. Pediatric PTCs have distinct clinical and pathological features and …

NTRK1/3 rearrangements have been reported in 2.3–3.4% of papillary thyroid carcinoma
(PTC) and are regarded as potential therapeutic targets. Recently, the application of …

ALK fusions are found in various tumors, including thyroid cancer, and serve as a diagnostic
marker and therapeutic target. Spectrum and outcomes of ALK fusions found in thyroid …

Over the past 3 decades, advances in the molecular genetics of thyroid cancer (TC) have
been translated into diagnostic tests, prognostic markers, and therapeutic agents. The main …

Pediatric papillary thyroid carcinoma (PPTC) is clinically distinct from adult-onset disease.
Although there are higher rates of metastasis and recurrence in PPTC, prognosis remains …

Thyroid cancer, a cancerous tumor or growth located within the thyroid gland, is the most
common endocrine cancer. It is one of the few cancers whereby incidence rates have …

The past decade has brought significant advances in our understanding of the molecular
mechanisms of thyroid carcinogenesis. Among thyroid carcinomas, the most successful …